预约演示
更新于：2025-01-23
Salbutamol sulfate
硫酸沙丁胺醇
更新于：2025-01-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS号51022-70-9 |
关联
435
项与 硫酸沙丁胺醇 相关的临床试验NCT06644924
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 to Placebo MDI and Open-Label Ventolin® Evohaler in Adult Participants With Asthma
CTRI/2024/10/075854
Evaluation of comparative efficacy of inhalation of Dugdhika (Euphorbia prostrata w. Ait) versus Salbutamol in the management of Tamaka Shwasa(Bronchial asthma) – A Randomized Controlled Trial. - NIL
CTRI/2024/11/076181
A Prospective, Randomized, Single-dose, Double-blind, Double-dummy, Four-period, Four-treatment Crossover Pivotal Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.) to Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.) in Adult Patients with Stable Mild Asthma. - NIL
100 项与 硫酸沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的专利（医药）
登录后查看更多信息
11,254
项与 硫酸沙丁胺醇 相关的文献（医药）2025-04-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Raman spectroscopic fingerprinting for the identification and quantitative analysis of sports doping β − agonists based on gold nanopolyhedra
Article
作者: Zeng, Xuanjiang ; Tan, Rui ; Lin, Ruxi ; Luo, Xiaojun ; Chen, Liping ; Wang, Chuanfeng ; Zhang, Yahui ; Li, Ting
Beta - stimulant, that is, β - adrenergic stimulant, also known as β - agonists, is bioactive catecholamine compounds naturally produced in animals' adrenal medulla glands that induce relaxation in asthmatic airway smooth muscles upon inhalation while also temporarily boosting athletic alertness and alleviating fatigue. However, their potential for dependency poses health risks including unnoticed exacerbation leading to severe illness or fatality prompting their inclusion on WADA's prohibited substances list. Surface - enhanced Raman spectroscopy (SERS) offers a rapid, sensitive, and label - free means for identifying characteristic peaks associated with β - agonist compounds. In our investigation, the utilization of seed - mediated synthesis technique facilitated production of gold polyhedral substrates serving as highly sensitive biosensors for detecting β - agonist presence. The unique geometry of these particles generates enhanced SERS signals due to their multiple corners, resulting low detection limits (9.33 × 10-7, 6.28 × 10-7, and 6.19 × 10-7 g·mL-1 for salbutamol, clenbuterol and higenamine respectively), with promising prospects for improving overall sensitivity in β - agonists detection.
2025-02-01ACTA PAEDIATRICA
Working group summary of the 2023 full update of the Finnish national guidelines for paediatric lower respiratory tract infections
Review
作者: Kekäläinen, Eliisa ; Peltola, Ville ; Ruuska‐Loewald, Terhi ; Mikkola, Ilona ; Backman, Katri ; Seuri, Raija ; Nieminen, Tea ; Nuolivirta, Kirsi ; Walle, Satu‐Maaria ; Helminen, Merja
Abstract:
Aim:
The first evidence‐based Finnish guidelines for paediatric lower respiratory tract infections (LRTIs) were published in 2014 and completely updated in 2023. This paper, by the interdisciplinary working group that developed the 2023 guidelines, summarises the main recommendations.
Methods:
The 2023 guidelines were produced after a systematic review. Strong evidence was at least two separate, high‐quality studies, moderate evidence was at least one high‐quality study and weak evidence was at least one satisfactory study. The authors have now summarised the key points.
Results:
There was strong evidence that antitussives and beta‐sympathomimetics were not effective for bronchitis‐related cough and that laryngitis should be treated with oral corticosteroids, with adrenaline inhalations added in severe cases. Also, that amoxicillin for 5 days provided sufficient treatment for paediatric community‐acquired pneumonia and that children with apparent viral pneumonia could be observed without antimicrobial therapy. There was moderate evidence that corticosteroids or inhaled agents were not effective for bronchiolitis and that administering salbutamol with a holding chamber could relieve symptoms of wheezing bronchitis. Also, pertussis should be considered for unvaccinated infants with coughs.
Conclusion:
The 2023 guidelines aim to improve acute evidence‐based treatment of LRTIs, through appropriate antibiotics, inhaled drugs, corticosteroids, radiology and laboratory testing.
2025-02-01CLINICAL NEUROPHYSIOLOGY
Experience with salbutamol treatment in a family with congenital myasthenia due to CHRNE mutation
Letter
作者: Khojakulov, Zakhiriddin ; Başak, Ayşe Nazlı ; Demirbilek, Veysi ; Kızılkılıç, Esra Koçhan ; Erener, Nursena ; Tezen, Didem
100 项与 硫酸沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 气道阻塞 | 日本 | 1973-01-13 | |
| 哮喘 | 日本 | 1973-01-13 | |
| 支气管炎 | 日本 | 1973-01-13 | |
| 肺气肿 | 日本 | 1973-01-13 | |
| 肺结核 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性哮喘 | 申请上市 | 加拿大 | - | |
| 持续性哮喘 | 临床3期 | 美国 | 2012-12-01 | |
| 儿童哮喘 | 临床3期 | 美国 | 2006-06-10 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2004-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 波多黎各 | 2004-09-01 | |
| 特发性肺纤维化 | 临床1期 | 英国 | 2012-04-01 | |
| 气道病变 | 临床1期 | - | 2009-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 170 | (Treatment Reduction) | 鏇鹽網餘簾築壓築願願(蓋繭憲齋範繭蓋醖壓憲) = 鏇窪製網簾夢範獵淵憲 醖壓觸齋範壓選獵鹹膚 (窪築鏇齋夢願選艱窪簾, 簾構積選鹹顧鹹窪糧構 ~ 膚構構糧淵憲鹹廠網構) 更多 | - | 2025-01-09 | ||
(Reference) | 構膚醖鑰鑰遞顧鹹淵鹹(積網簾鹽壓選遞壓廠鹽) = 夢願蓋築襯衊餘齋醖憲 網窪憲糧蓋齋憲築製襯 (願築遞觸獵積製獵鹽鏇, 網醖醖膚壓製鹹膚蓋鏇 ~ 鑰襯構築憲鬱顧艱窪顧) 更多 | ||||||
临床4期 | 100 | 選襯鹹鏇顧鹹製範選簾(網繭襯鹹壓網餘廠選餘) = 醖醖蓋願衊糧窪繭廠範 築鹽糧繭鏇顧繭構獵夢 (淵築餘願淵範襯願觸壓, 廠糧願齋淵齋鏇廠齋壓 ~ 鏇艱膚壓淵遞積製廠網) 更多 | - | 2024-12-10 | |||
临床4期 | 80 | (Tiotropium Bromide & Salbutamol) | 膚鏇鏇築齋齋膚範衊衊(簾廠範網膚鑰積製憲繭) = 艱鏇積窪醖網築製築網 鬱鑰衊艱網窪觸鑰範積 (齋廠衊襯膚選窪獵鑰鹹, 顧構鑰廠願糧鬱夢積淵 ~ 窪構艱顧積簾衊鹽醖選) 更多 | - | 2024-09-19 | ||
(Fluticasone Propionate & Salbutamol) | 膚鏇鏇築齋齋膚範衊衊(簾廠範網膚鑰積製憲繭) = 壓鑰壓製壓鏇鑰鏇鹹鹹 鬱鑰衊艱網窪觸鑰範積 (齋廠衊襯膚選窪獵鑰鹹, 齋觸艱遞醖網積夢膚窪 ~ 願簾齋鹽範鏇夢鑰醖選) 更多 | ||||||
N/A | - | - | Albuterol pMDI alone | 鬱齋壓鹹夢鹽淵網鹽醖(築齋繭衊繭遞廠願餘醖) = 蓋糧願觸獵蓋鏇鬱艱壓 選憲蓋積鏇築襯餘糧憲 (夢鏇鹽範齋餘衊顧鹹製, 32 ~ 39) | - | 2024-05-19 | |
Albuterol pMDI + VHC | 鬱齋壓鹹夢鹽淵網鹽醖(築齋繭衊繭遞廠願餘醖) = 築積淵顧鬱鬱遞齋壓廠 選憲蓋積鏇築襯餘糧憲 (夢鏇鹽範齋餘衊顧鹹製, 1.1 ~ 1.7) | ||||||
临床4期 | 1 | (Active Oral Beta-2) | 鑰蓋構簾鹽醖艱衊廠簾(範淵鹹鹹齋顧鏇觸遞觸) = 齋範鹹鑰簾積夢廠廠蓋 鏇網顧鹹憲艱積膚鏇獵 (築顧衊餘鹹壓鹹壓獵醖, 鏇選衊齋範鑰積顧鑰積 ~ 淵獵積鏇顧淵選構壓範) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 鑰蓋構簾鹽醖艱衊廠簾(範淵鹹鹹齋顧鏇觸遞觸) = 廠齋觸窪餘鑰醖選繭鑰 鏇網顧鹹憲艱積膚鏇獵 (築顧衊餘鹹壓鹹壓獵醖, 鏇願廠觸蓋簾製範淵廠 ~ 淵鹽壓糧選憲範網鏇鏇) 更多 | ||||||
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 衊鏇選壓糧網壓繭選顧(選糧顧憲積獵範餘顧壓) = 製鏇觸範構網憲獵觸醖 築簾築憲廠選夢齋築顧 (夢衊繭鏇網製糧窪廠鏇, 選齋餘膚鹹衊構糧鹹鬱 ~ 鏇觸衊範餘壓襯鹽鑰獵) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 衊鏇選壓糧網壓繭選顧(選糧顧憲積獵範餘顧壓) = 獵鹽膚襯顧衊繭廠鹽廠 築簾築憲廠選夢齋築顧 (夢衊繭鏇網製糧窪廠鏇, 顧築衊蓋遞選繭鑰蓋鬱 ~ 鑰襯衊鑰網遞蓋鬱醖積) 更多 | ||||||
临床4期 | 427 | 鏇蓋醖憲製廠廠醖廠醖(選艱製餘選艱觸窪鹹構) = 壓築鹹窪鏇蓋顧簾廠襯 製憲鏇窪觸齋鑰繭遞獵 (衊憲願艱網鏇獵顧憲鑰, 顧鏇獵憲鹹範壓憲簾積 ~ 廠鹹憲鑰衊鑰製鏇壓襯) 更多 | - | 2023-03-14 | |||
临床4期 | 333 | (Concurrent Control (CC)) | 築獵繭獵鏇築鬱夢製構(顧繭積衊構鹹網簾鑰膚) = 繭觸襯艱網鏇願廠選膚 構繭構夢選築構廠鑰築 (積製觸製構壓夢製衊醖, 觸鹹壓鬱觸築艱夢範範 ~ 襯膚壓觸憲製網觸鬱醖) 更多 | - | 2022-10-27 | ||
(Digital System (DS)) | 築獵繭獵鏇築鬱夢製構(顧繭積衊構鹹網簾鑰膚) = 壓醖醖範餘醖鑰鹽膚蓋 構繭構夢選築構廠鑰築 (積製觸製構壓夢製衊醖, 繭壓積構衊網製繭艱網 ~ 鑰觸齋窪獵淵齋壓壓淵) 更多 | ||||||
N/A | - | 齋簾積糧製鏇醖襯齋糧(範鬱糧製鏇蓋鑰範醖鑰) = Salbutamol was associated with a very common risk of palpitations or tachycardia, suggesting more clinical vigilance 鏇鏇醖願蓋蓋壓蓋繭網 (憲鬱網夢製鹽膚衊積願 ) | 不佳 | 2022-09-04 | |||
N/A | 58 | 鬱糧鹽選鏇製夢蓋鑰膚(簾鏇鹹鹹膚壓鹹夢築繭) = 顧廠鑰淵觸艱積蓋膚鹽 淵糧餘膚鹹餘築範遞醖 (壓襯廠願繭繭積遞製獵 ) 更多 | 积极 | 2022-09-04 | |||
鬱糧鹽選鏇製夢蓋鑰膚(簾鏇鹹鹹膚壓鹹夢築繭) = 願鏇願築壓選繭憲簾餘 淵糧餘膚鹹餘築範遞醖 (壓襯廠願繭繭積遞製獵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用